{{expert|time=2017-09-05T07:07:25+00:00}}
{{Copy edit|time=2021-11-13T02:37:27+00:00}}
{{medical}}
{{Infobox disease
| Name        = 高脂血症<br />({{lang|en|Hyperlipidemia}})
| Image       = Hyperlipidaemia - lipid in EDTA tube.jpg
| Caption     = 一個4毫升樣品的高脂血，無離心靜置四小時後，其脂質分離至管上半部（样品在[[乙二胺四乙酸|EDTA]]真空採血管中）
| ICD10       = {{ICD10|E|78||e|70}}
| ICD9        = {{ICD9|272.0}}-{{ICD9|272.4}}
| Field       = [[心血管|心血管]]
| DiseasesDB  = 6255
| MeshID      = D006949
}}

'''高脂血症'''（{{Lang|en|Hyperlipidemia}}，[[英式英文|英式英文]]為 {{Lang|en-GB|Hyperlipidaemia}}）又稱'''高脂蛋白血症'''（Hyperlipoproteinemia），俗稱'''血脂過高'''、'''高血脂'''，是指涉及[[血液|血液]]任何或所有[[脂類|脂類]]以及又或[[脂蛋白|脂蛋白]]異常升高水平的情況<ref name=DorlandAndAmericanHeritage>[http://medical-dictionary.thefreedictionary.com/hyperlipidemia thefreedictionary.com > hyperlipidemia] {{Wayback|url=http://medical-dictionary.thefreedictionary.com/hyperlipidemia |date=20110612045514 }} Citing:*Dorland's Medical Dictionary for Health Consumers. 2007 by Saunders, an imprint of Elsevier *The American Heritage Medical Dictionary. 2007, 2004 by Houghton Mifflin Company.</ref>，是[[血脂異常|血脂異常]]（Dyslipidemia）最常見的形式（其中包括任何異常脂質水平）。脂質（脂溶性分子）由 [[载脂蛋白|载脂蛋白]]運送。 [[载脂蛋白|载脂蛋白]]密度及结构类型決定该[[载脂蛋白|载脂蛋白]]如何對代謝产生影響。血中[[脂類|脂质]](Lipid)主要的成分有[[膽固醇|膽固醇]](cholesterol; CE)、[[三酸甘油酯|三酸甘油酯]](triglyceride; TG)與[[磷脂|含磷脂类]](phospholipid)，因不溶於水，必須先與载脂蛋白AІ、载脂蛋白B100結合成可溶性的脂蛋白(Lipoprotein)才可運行於血液中，輸送到全身各部位。[[高密度脂蛋白|高密度脂蛋白]](HDL-C)可以移除血液中多的膽固醇，而[[低密度脂蛋白|低密度脂蛋白]](LDL-C)含有大量[[膽固醇|膽固醇]]，容易造成[[动脉粥样硬化|動脈粥样硬化]]。<ref name="Basic & Clinical Pharmacology">{{cite book | author=Katzung and Trevor|title=Agents used in Dyslipidemia|publisher=McGraw Hill|location=San Francisco |isbn=9781259252907|chapter=35 |edition=13th ed|year=2015}}</ref><ref name="藥理學">{{Cite book | author=蔡秋帆、湯念湖、王耀宏合著 | title=藥理學 2014 | publisher=新文京開發有限公司 | year=2014}}</ref>。

脂蛋白依其組成及密度之不同可分為五類：乳糜微粒(chylomicron; CM)、極低密度脂蛋白(very low density lipoprotein; VLDL)、低密度脂蛋白(low density lipoprotein; LDL)、中密度脂蛋白(intermediate density lipoprotein; IDL)、高密度脂蛋白(high density lipoprotein; HDL。<ref name="Basic & Clinical Pharmacology">{{cite book | author=Katzung and Trevor|title=Agents used in Dyslipidemia|publisher=McGraw Hill|location=San Francisco |isbn=9781259252907|chapter=35 |edition=13th ed|year=2015}}</ref><ref name="藥理學">{{Cite book | author=蔡秋帆、湯念湖、王耀宏合著 | title=藥理學 2014 | publisher=新文京開發有限公司 | year=2014}}</ref>。

高脂血症分為「原發性」和「繼發性亞型」。原發性高脂血症通常來自於遺傳原因（例如在受體蛋白中的突變），而繼發性高脂血症的產生是由於其它的原因，如[[糖尿病|糖尿病]]。脂質和脂蛋白異常是在一般人群較常見的，並且被認為是[[心血管疾病|心血管疾病]]的一個改變的危險因素、起於[[动脉粥样硬化|动脉粥样硬化]]對它們發生影響。此外，某些形式的高脂血症可能誘發{{Tsl|en|Acute pancreatitis|急性胰腺炎}}<ref name="Basic & Clinical Pharmacology">{{cite book | author=Katzung and Trevor|title=Agents used in Dyslipidemia|publisher=McGraw Hill|location=San Francisco |isbn=9781259252907|chapter=35 |edition=13th ed|year=2015}}</ref>。

==分類==<!--
Hyperlipidemias may basically be classified as either familial (also called primary<ref name=Chait>{{cite journal |author=Chait A, Brunzell JD |title=Acquired hyperlipidemia (secondary dyslipoproteinemias) |journal=Endocrinol. Metab. Clin. North Am. |volume=19 |issue=2 |pages=259–78 |date=June 1990 |pmid=2192873 |doi= |url=https://archive.org/details/sim_endocrinology-and-metabolism-clinics-of-north-america_1990-06_19_2/page/259}}</ref>) caused by specific genetic abnormalities, or acquired (also called secondary)<ref name=Chait/> when resulting from another underlying disorder that leads to alterations in plasma lipid and lipoprotein metabolism.<ref name=Chait/> Also, hyperlipidemia may be idiopathic, that is, without known cause.

Hyperlipidemias are also classified according to which types of lipids are elevated, that is [[hypercholesterolemia|hypercholesterolemia]], [[hypertriglyceridemia|hypertriglyceridemia]] or both in [[combined_hyperlipidemia|combined hyperlipidemia]]. Elevated levels of [[Lipoprotein(a)|Lipoprotein(a)]] may also be classified as a form of hyperlipidemia.-->

===家族性(原發性)===<!--
Familial hyperlipidemias are classified according to the [[Donald_S._Fredrickson|Fredrickson]] classification, which is based on the pattern of lipoproteins on [[electrophoresis|electrophoresis]] or [[Ultracentrifuge|ultracentrifugation]].<ref>{{cite journal | last1 = Fredrickson | first1 = DS | last2 = Lees | first2 = RS | title = A system for phenotyping hyperlipoproteinemia | journal = Circulation | volume = 31 | pages = 321–7 | year = 1965 | pmid = 14262568 | url=http://circ.ahajournals.org/cgi/reprint/31/3/321 | format=PDF | issue=3 | doi = 10.1161/01.CIR.31.3.321}}</ref> It was later adopted by the [[World_Health_Organization|World Health Organization]] (WHO). It does not directly account for [[High_density_lipoprotein|HDL]], and it does not distinguish among the different [[genes|genes]] that may be partially responsible for some of these conditions.
-->
{| class="wikitable" class="sortable wikitable"
|+ '''高脂血症的弗雷德里克森分类法'''
|-
  !colspan=2| 高脂蛋白血症
  ! [[OMIM|OMIM]]
  ! 同义词
  ! 缺陷
  ! 增加的脂蛋白
  ! 主要症状
  ! 治疗
  ! 血清外观
  ! 预估的流行程度
|-
  !rowspan=3| [[Type_I_hyperlipoproteinemia|I 型]]
  ! [[Hyperlipoproteinemia_type_Ia|a]]
  | {{OMIM2|238600}}
  | Buerger-Gruetz综合征或家族性高胆固醇血症
  | [[脂蛋白酯酶|脂蛋白酯酶]] (LPL)减少
  |rowspan=3| [[乳糜微粒|乳糜微粒]]
  |rowspan=3| [[急性胰腺炎|急性胰腺炎]], [[lipemia_retinalis|视网膜脂血症]], 皮肤出现黄色瘤, [[肝脾肿大|肝脾肿大]]
  |rowspan=3| 饮食控制
  |rowspan=3| 顶层奶油状
  |rowspan=3| 1/1,000,000<ref>[http://www.cags.org.ae/FMPro?-DB=ctga.fp5&-Format=ctga/ctga_detail.html&-RecID=34563&-Find Hyperlipoproteinemia, Type I] {{webarchive|url=https://web.archive.org/web/20120327213629/http://www.cags.org.ae/FMPro?-DB=ctga.fp5&-Format=ctga%2Fctga_detail.html&-RecID=34563&-Find |date=2012-03-27 }} from Centre for Arab Genomic Studies. Retrieved July 2011. Citing: "About 1:1,000,000 people are affected with Hyperlipoproteinemia type I worldwide with a higher prevalence in some regions of Canada."</ref>
|-
  ! [[hyperlipoproteinemia_type_Ib|b]]
  | {{OMIM2|207750}}
  | 家族性载脂蛋白CII缺乏症
  | [[apolipoprotein_C2|载脂蛋白CII]]减少
|-
  ! [[Hyperlipoproteinemia_type_Ic|c]]
  | {{OMIM2|118830}}
  |
  | 血液中的[[LPL|脂蛋白酯酶]]抑制剂
|-
  !rowspan=2| II 型
  ! a
  | {{OMIM2|143890}}
  | [[家族性高胆固醇血症|家族性高胆固醇血症]]
  | [[低密度脂蛋白受體|低密度脂蛋白受体]]数量不足
  | [[LDL|低密度脂蛋白]]
  | [[黄色瘤|黄色瘤]], [[老年环|老年环]], 肌腱黄色瘤
  | [[胆汁螯合剂|胆汁螯合剂]], [[他汀|他汀]]、 [[烟酸|烟酸]]
  | 澄清
  | 杂合子几率为1/500
|-
  ! b
  | {{OMIM2|144250}}
  | 家族性混合型高脂血症
  | [[低密度脂蛋白受體|低密度脂蛋白受体]]减少和[[载脂蛋白B|载脂蛋白B100]]增加
  | [[LDL|低密度脂蛋白]] 和[[極低密度脂蛋白|極低密度脂蛋白]]
  |
  | 他汀类, [[烟酸|烟酸]], [[贝特类|贝特类]]
  | 澄清
  | 1/100
|-
  !colspan=2| III 型
  | {{OMIM2|107741}}
  | [[Familial_dysbetalipoproteinemia|家族性异常β脂蛋白血症]]
  | Defect in [[apolipoprotein_E|Apo E 2]] synthesis
  | [[Intermediate_density_lipoprotein|IDL]]
  | 结节性黄瘤，发疹性黄瘤，掌黄瘤
  | 贝特类药物, 他汀类药物
  | 浑浊
  | 1/10,000<ref name=fung2011>{{cite journal | last1 = Fung | first1 = M. | last2 = Hill | first2 = J. | last3 = Cook | first3 = D. | last4 = Frohlich | first4 = J. | title = Case series of type III hyperlipoproteinemia in children | journal = Case Reports | volume = 2011 | pages = bcr0220113895 | year = 2011 | pmid =  | pmc =  | doi = 10.1136/bcr.02.2011.3895 }}</ref>
|-
  !colspan=2| IV 型
  | {{OMIM2|144600}}
  | [[家族性高甘油三酯血症|家族性高甘油三酯血症]]
  | VLDL生成增加并且清除率减低
  | VLDL
  | 高水平时会导致胰腺炎
  | 贝特类, 烟酸, 他汀类
  | 浑浊
  | 1/100
|-
  !colspan=2| [[#type_V|V 型]]
  | {{OMIM2|144650}}
  | 
  | VLDL生成增加并且[[LPL|LPL]]减少
  | VLDL和乳糜颗粒
  |
  | 烟酸, 贝特类
  | 顶层奶油状和底层浑浊
  | 
|}

[[File:Relative_prevalence_of_familial_hyperlipoproteinemias.png|thumb]]

====高脂蛋白血症Ⅰ型====<!--
{{anchor|type I}}
Type I hyperlipoproteinemia exists in several forms:
*[[Lipoprotein_lipase_deficiency|Lipoprotein lipase deficiency (type Ia)]], due to a deficiency of [[lipoprotein_lipase|lipoprotein lipase]] (LPL) or altered [[apolipoprotein_C2|apolipoprotein C2]], resulting in elevated [[chylomicron|chylomicron]]s, the particles that transfer fatty acids from the [[digestive_tract|digestive tract]] to the [[liver|liver]]
*Familial apoprotein CII deficiency (type Ib),<ref>[http://omim.org/entry/207750 OMIM entry 207750] last updated 02/10/2009</ref><ref>{{cite journal | last1 = Yamamura | first1 = T. | last2 = Sudo | first2 = H. | last3 = Ishikawa | first3 = K. | last4 = Yamamoto | first4 = A. | title = Familial type I hyperlipoproteinemia caused by apolipoprotein C-II deficiency | journal = Atherosclerosis | volume = 34 | issue = 1 | pages = 53–65 | year = 1979 | pmid = 227429 | doi = 10.1016/0021-9150(79)90106-0 }}</ref> a condition caused by a lack of lipoprotein lipase activator.<ref name="Andrews">{{cite book |author=James, William D.; Berger, Timothy G.; et al. |title=Andrews' Diseases of the Skin: clinical Dermatology |publisher=Saunders Elsevier |location= |year=2006 |pages= |isbn=0-7216-2921-0 |oclc= |doi= |accessdate=}}</ref>{{rp|533}}
*Chylomicronemia due to circulating inhibitor of lipoprotein lipase (type Ic)<ref>[http://omim.org/entry/118830 OMIM entry 118830] updated 03/18/2004</ref>

Type I hyperlipoproteinemia usually presents in childhood with eruptive xanthomata and abdominal colic. Complications include retinal vein occlusion, acute pancreatitis, steatosis and organomegaly, and lipaemia retinalis.-->

====高脂蛋白血症II型====<!--
Hyperlipoproteinemia type II, by far the most common form, is further classified into types IIa and IIb, depending mainly on whether elevation in the triglyceride level occurs in addition to LDL cholesterol.-->

=====IIa型=====
{{main|家族性高胆固醇血症}}
<!--
This may be sporadic (due to dietary factors), polygenic, or truly familial as a result of a mutation either in the [[LDL_receptor|LDL receptor]] gene on [[chromosome_19|chromosome 19]] (0.2% of the population) or the [[apolipoprotein_B|ApoB]] gene (0.2%). The familial form is characterized by [[Xanthoma|tendon xanthoma]], [[xanthelasma|xanthelasma]], and premature cardiovascular disease.  The incidence of this disease is about one in 500 for heterozygotes, and one in 1,000,000 for homozygotes.

HLPIIa is a rare genetic disorder characterized by increased levels of LDL cholesterol in the blood due to the lack of uptake (no Apo B receptors) of LDL particles. This pathology, however, is the second-most common disorder of the various hyperlipoproteinemias, with individuals with a heterozygotic predisposition of one in every 500 and individuals with homozygotic predisposition of one in every million. These individuals may present with a very unique set of physical characteristics such as: xanthelasmas (yellow deposits of fat underneath the skin often presenting in the nasal portion of the eye), tendon and tuberous xanthomas, arcus juvenilis (the graying of the eye often characterized in older individuals), arterial bruits, claudication, and of course atherosclerosis. Laboratory findings for these individuals are obvious and yet interesting because their serum cholesterol levels are two to three times greater than normal, as well as increased LDL cholesterol, but their triglycerides and VLDL values fall in the normal ranges. To manage persons with HLPIIa, drastic measures may need to be taken, especially if their HDL cholesterol levels are less than 30 mg/dl and their LDL levels are greater than 160 mg/dl. A proper diet for these individuals requires a decrease in total fat to less than 30% of total calories with a ratio of monounsaturated:polyunsaturated:saturated fat of 1:1:1. Cholesterol should be reduced to less than 300 mg/day, thus the avoidance of animal products and to increase fiber intake to more than 20 g/day with 6g of soluble fiber/day.{{cn|date=October 2014}} Exercise should be promoted, as it can increase HDL. The overall prognosis for these individuals is in the worst-case scenario if uncontrolled and untreated individuals may die before the age of 20, but if one seeks a prudent diet with correct medical intervention, the individual may see an increased incidence of xanthomas with each decade, and Achilles tendinitis  and accelerated atherosclerosis will occur.-->

=====IIb型=====<!--
The high VLDL levels are due to overproduction of substrates, including triglycerides, acetyl CoA, and an increase in B-100 synthesis. They may also be caused by the decreased clearance of LDL. Prevalence in the population is 10%.
* Familial combined hyperlipoproteinemia (FCH)
* [[Lysosomal_acid_lipase_deficiency|Lysosomal acid lipase deficiency]], often called ([[Cholesteryl_ester_storage_disease|Cholesteryl ester storage disease]])
* Secondary combined hyperlipoproteinemia (usually in the context of [[metabolic_syndrome|metabolic syndrome]], for which it is a diagnostic criterion)-->

====高脂蛋白血症Ⅲ型====<!--
This form is due to high [[chylomicron|chylomicron]]s and IDL (intermediate density lipoprotein). Also known as ''broad beta disease'' or ''dysbetalipoproteinemia'', the most common cause for this form is the presence of [[Apolipoprotein_E|ApoE]] E2/E2 genotype. It is due to cholesterol-rich VLDL (β-VLDL). Its prevalence has been estimated to be approximately 1 in 10,000.<ref name=fung2011/>

It is associated with hypercholesterolaemia (typically 8-12 mmol/L), hypertriglyceridaemia (typically 5-20 mmol/L), a normal ApoB concentration, and two types of skin signs (palmar xanthomata or orange discoloration of skin creases, and tuberoeruptive xanthomata on the elbows and knees). It is characterized by the early onset of cardiovascular disease and peripheral vascular disease. Remnant hyperlipidaemia occurs as a result of abnormal function of the ApoE receptor, which is normally required for clearance of chylomicron remnants and IDL from the circulation. The receptor defect causes levels of chylomicron remnants and IDL to be higher than normal in the blood stream. The receptor defect is an autosomal recessive mutation or polymorphism.-->

====高脂蛋白血症Ⅳ型====<!--
[[Familial_hypertriglyceridemia|Familial hypertriglyceridemia]] is an autosomal dominant condition occurring in approximately 1% of the population.<ref name=Boman1975>Boman H, Hazzard WR, AlbersJJ, et ah Frequency of monogenic forms of hyperlipidemia in a normal population. AmJ ttum Genet 27:19A,1975. [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1762895/pdf/ajhg00439-0130.pdf]</ref>-->

====高脂蛋白血症V型====<!--
{{anchor|type V}}Hyperlipoproteinemia type V, also known as mixed hyperlipoproteinemia familial or mixed hyperlipidemia,<ref>{{cite web | url=http://www.medilexicon.com/medicaldictionary.php?s=type+5+hyperlipidemia | title=Medical Definition Search For 'Type 5 Hyperlipidemia | publisher=medilexicon | accessdate=1 November 2013}}</ref> is very similar to type I, but with high [[VLDL|VLDL]] in addition to chylomicrons.

It is also associated with glucose intolerance and hyperuricemia

In medicine, combined hyperlipidemia (or -aemia) (also known as "multiple-type hyperlipoproteinemia") is a commonly occurring form of hypercholesterolemia (elevated cholesterol levels) characterised by increased LDL and triglyceride concentrations, often accompanied by decreased HDL.<ref name=Elsevier>[http://medical-dictionary.thefreedictionary.com/hyperlipidemia thefreedictionary.com > hyperlipidemia] Citing:
*Saunders Comprehensive Veterinary Dictionary, 3 ed. 2007 by Elsevier</ref> On lipoprotein electrophoresis (a test now rarely performed) it shows as a hyperlipoproteinemia type IIB. It is the most common inherited lipid disorder, occurring in about one in 200 persons. In fact, almost one in five individuals who develop coronary heart disease before the age of 60 have this disorder.
The elevated triglyceride levels (>5 mmol/l) are generally due to an increase in very low density lipoprotein (VLDL), a class of lipoprotein prone to cause atherosclerosis.

Types
# Familial combined hyperlipidemia (FCH) is the familial occurrence of this disorder, probably caused by decreased LDL receptor and increased ApoB.
# FCH is extremely common in patients who suffer from other diseases from the metabolic syndrome ("syndrome X", incorporating diabetes mellitus type II, hypertension, central obesity and CH). Excessive free fatty acid production by various tissues leads to increased VLDL synthesis by the liver. Initially, most VLDL is converted into LDL until this mechanism is saturated, after which VLDL levels elevate.

Both conditions are treated with fibrate drugs, which act on the peroxisome proliferator-activated receptors (PPARs), specifically PPARα, to decrease free fatty acid production.
Statin drugs, especially the synthetic statins (atorvastatin and rosuvastatin) can decrease LDL levels by increasing hepatic reuptake of LDL due to increased LDL-receptor expression.-->

====未分類的家族型====<!--
These unclassified forms are extremely rare:
* [[Hyperalphalipoproteinemia|Hyperalphalipoproteinemia]]
* [[Polygenic_hypercholesterolemia|Polygenic hypercholesterolemia]]-->

===後天性(繼發性)===
後天性的高脂血症（也稱為繼發性"異常脂蛋白血症"(dyslipoproteinemia)）常常摹拟原發性高脂血症的形式，並且可以具有相似的結果。<ref name=Chait>{{cite journal |author=Chait A, Brunzell JD |title=Acquired hyperlipidemia (secondary dyslipoproteinemias) |journal=Endocrinol. Metab. Clin. North Am. |volume=19 |issue=2 |pages=259–78 |date=June 1990 |pmid=2192873 |doi= |url=https://archive.org/details/sim_endocrinology-and-metabolism-clinics-of-north-america_1990-06_19_2/page/259}}</ref> <!--They may result in increased risk of premature [[atherosclerosis|atherosclerosis]] or, when associated with marked [[hypertriglyceridemia|hypertriglyceridemia]], may lead to [[pancreatitis|pancreatitis]] and other complications of the [[chylomicronemia_syndrome|chylomicronemia syndrome]].<ref name=Chait/> The most common causes of acquired hyperlipidemia are:
* [[diabetes_mellitus|diabetes mellitus]]<ref name=Chait/>
* Use of drugs such as [[diuretics|diuretics]],<ref name=Chait/> [[beta_blockers|beta blockers]],<ref name=Chait/> and [[estrogens|estrogens]]<ref name=Chait/>

Other conditions leading to acquired hyperlipidemia include:
* Hypothyroidism<ref name=Chait/>
* [[Renal_failure|Renal failure]]<ref name=Chait/>
* [[Nephrotic_syndrome|Nephrotic syndrome]]<ref name=Chait/>
* [[Alcohol_consumption|Alcohol consumption]]<ref name=Chait/>
* Some rare [[endocrine_disorder|endocrine disorder]]s<ref name=Chait/> and [[metabolic_disorders|metabolic disorders]]<ref name=Chait/>
Treatment of the underlying condition, when possible, or discontinuation of the offending drugs usually leads to an improvement in the hyperlipidemia. Specific lipid-lowering therapy may be required in certain circumstances.{{citation needed|date=June 2012}}

Another acquired cause of hyperlipidemia, although not always included in this category, is postprandial hyperlipidemia, a normal increase following ingestion of food.<ref name=Elsevier>[http://medical-dictionary.thefreedictionary.com/hyperlipidemia thefreedictionary.com > hyperlipidemia] Citing:
*Saunders Comprehensive Veterinary Dictionary, 3 ed. 2007 by Elsevier</ref><ref name="BioMed Central">{{cite article|url=http://www.cardiab.com/content/10/1/61|postscript=none|separator=,|author1=Sameer Ansar|author2=Juraj Koska|author3=Peter D Reaven|title=Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: Role of Incretins|journal=Cardiovascular Diabetology}}</ref>-->

==治療==
人體內各組織細胞都含有豐富的膽固醇，才能維持正常的生理功能，膽固醇的功能如構成人體細胞膜的重要成分，是固醇類荷爾蒙、維生素D及膽汁的最主要原料。
因此，降低血脂肪〈特別是第Ⅱ型)首先應重視飲食療法，減少膽固醇食物（如蛋黃、動物內臟、海鮮類）之攝取，多攝取含不飽和性脂肪酸之食物（植物油如橄欖油或葵花子油等）；另外，維持標準體重、避免吸菸及喝酒、養成良好運動習慣，對降血脂也有助益<ref name="Basic & Clinical Pharmacology">{{cite book | author=Katzung and Trevor|title=Agents used in Dyslipidemia|publisher=McGraw Hill|location=San Francisco |isbn=9781259252907|chapter=35 |edition=13th ed|year=2015}}</ref><ref name="藥理學">{{Cite book | author=蔡秋帆、湯念湖、王耀宏合著 | title=藥理學 2014 | publisher=新文京開發有限公司 | year=2014}}</ref>。已有很多證據發現植物中的植固醇及富含[[Ω-3脂肪酸|Ω-3脂肪酸]]的食物有益下降總膽固醇 .<ref>{{cite journal | last1 = Thompson | first1 = GR | title = Management of dyslipidaemia | journal = Heart (British Cardiac Society) | volume = 90 | issue = 8 | pages = 949–55 | year = 2004 | pmid = 15253984 | pmc = 1768388 | doi = 10.1136/hrt.2003.021287 }}</ref>

抗高血脂藥物(antihyperlipidemic drugs)之治療機轉主要分為以下三大點：
1. 降低體內合成總膽固醇。
2. 加速分解脂蛋白與促進排除膽固醇。
3. 增加HDL含量與抑制膽固醇吸收。

降血脂藥物可依不同機轉分為以下七大類:  <ref name="Basic & Clinical Pharmacology">{{cite book | author=Katzung and Trevor|title=Agents used in Dyslipidemia|publisher=McGraw Hill|location=San Francisco |isbn=9781259252907|chapter=35 |edition=13th ed|year=2015}}</ref><ref name="藥理學">{{Cite book | author=蔡秋帆、湯念湖、王耀宏合著 | title=藥理學 2014 | publisher=新文京開發有限公司 | year=2014}}</ref><ref>Mattar M, Obeid O. Fish oil and the management of hypertriglyceridemia. Nutr Health.  2009;20(1):41-9.</ref><ref>{{cite journal |last1=Michos |first1=Erin D. |last2=McEvoy |first2=John W. |last3=Blumenthal |first3=Roger S. |title=Lipid Management for the Prevention of Atherosclerotic Cardiovascular Disease |journal=New England Journal of Medicine |date=2019-10-17 |volume=381 |issue=16 |pages=1557–1567 |doi=10.1056/NEJMra1806939 |url=https://www.nejm.org/doi/full/10.1056/NEJMra1806939#article_citing_articles |issn=0028-4793 |access-date=2019-12-22 |archive-date=2019-12-12 |archive-url=https://web.archive.org/web/20191212025422/https://www.nejm.org/doi/full/10.1056/NEJMra1806939#article_citing_articles |dead-url=no }}</ref>。

第一類:降低膽固醇的生合成—Statins類：HMG-CoA還原酶抑制劑，例如:Atorvastatin(Lipitor® )、Lovastatin(Mevacor® )。

第二類:阻擋NPC1L1運送蛋白的作用，從而干擾膽固醇與脂質在腸道的吸收，當服藥者對Statins沒有治療作用或產生過敏反應時給予:Ezetimibe (Ezetrol® ); Orlistat（Xenical®；羅氏鮮® ；俗名：讓你酷）;β-Sitosterol 。

第三類:抑制PCSK9酶在LDL接收器上的分解作用，從而增加LDL接收器的數量並加速LDL在血清中的排除，例如：Evolocumab(Repatha® )。

第四類:Nicotinic acid（Niacin；菸鹼酸；Vit.B3）；Acipimox (Olbetam®)--為維生素B3製劑，大劑量可抑制脂肪組織之脂肪分解作用(lipolysis)，降低血漿及肝臟中的脂肪酸濃度，減少肝臟三酸甘油酯及VLDL之合成與分泌，間接降低血中LDL量；又可增加HDL的濃度，加速組織排除膽固醇。

第五類:促進膽固醇的排除—膽酸結合樹脂，例如:Cholestyramine(Questran® )。

第六類:加速低密度脂蛋白的分解，例如:Gemfibrozil (Lopid®)—纖維酸(Fibrates) 類藥物--Fenofibrate(Tricor® );  Clofibrate。

第七類：其他:Probucol (Lurselle® )--促進周邊組織合成apoprotein E(apoE)，並將LDL移向肝臟代謝 。

==參見==
* [[高脂蛋白血症亞型黃色瘤變異列表|高脂蛋白血症亞型黃色瘤變異列表]](List of xanthoma variants associated with hyperlipoproteinemia subtypes)
* [[混合性高脂血症|混合性高脂血症]](Combined hyperlipidemia)
*[[家族性高甘油三脂血症|家族性高甘油三脂血症]](Familial hypertriglyceridemia)

==註釋==
{{reflist|30em}}

==外部連結==
* [http://profiles.nlm.nih.gov/FF/Views/Exhibit/visuals/scientist.html The Fredrickson papers (with photos from early lipoprotein research)] {{Wayback|url=http://profiles.nlm.nih.gov/FF/Views/Exhibit/visuals/scientist.html |date=20100706072741 }}
* {{GPnotebook|745209914}}

{{Lipid metabolism disorders}}

[[Category:血脂紊亂|Category:血脂紊亂]]